Bristol-Myers Squibb Co.'s HCV ambitions did not die with Inhibitex Inc.'s INX-189. The pharma believes its next choice for all-oral regimen involving NS3 protease, NS5A protein and non-nucleoside NS5B inhibitors has the safety and convenience to compete with more advanced rivals in HCV genotype 1 infection.

Last week, BMS said the triple combination achieved competitive SVR rates in a Phase IIa trial.